Shares of ProMIS Neurosciences, Inc. (NASDAQ:PMN – Get Free Report) fell 5% on Friday . The stock traded as low as $1.30 and last traded at $1.30. 16,788 shares were traded during trading, a decline of 76% from the average session volume of 70,167 shares. The stock had previously closed at $1.37.
ProMIS Neurosciences Price Performance
The stock has a market cap of $24.65 million, a PE ratio of -1.76 and a beta of 0.62. The stock’s fifty day moving average is $1.58 and its 200-day moving average is $1.79.
ProMIS Neurosciences (NASDAQ:PMN – Get Free Report) last posted its quarterly earnings results on Thursday, August 8th. The company reported ($0.13) earnings per share for the quarter, beating the consensus estimate of ($0.14) by $0.01. On average, sell-side analysts expect that ProMIS Neurosciences, Inc. will post -0.24 EPS for the current fiscal year.
ProMIS Neurosciences Company Profile
ProMIS Neurosciences, Inc discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins.
Read More
- Five stocks we like better than ProMIS Neurosciences
- Quiet Period Expirations Explained
- GE Vernova’s Rally Could Continue as Wind Business Gains Ground
- 3 Healthcare Dividend Stocks to Buy
- DraftKings vs. DoubleDown: Growth in the Online Gambling Boom
- How to Calculate Retirement Income: MarketBeat’s Calculator
- Join UiPath’s AI Surge and Catch the Coming Stock Price Reversal
Receive News & Ratings for ProMIS Neurosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProMIS Neurosciences and related companies with MarketBeat.com's FREE daily email newsletter.
